Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2019

Open Access 01-12-2019 | Deep Brain Stimulation | Review

Parkinson’s disease in China: a forty-year growing track of bedside work

Authors: Gen Li, Jianfang Ma, Shishuang Cui, Yixi He, Qin Xiao, Jun Liu, Shengdi Chen

Published in: Translational Neurodegeneration | Issue 1/2019

Login to get access

Abstract

The number and health burden of Parkinson’s disease increase rapidly in China. It is estimated that China will have nearly half of the Parkinson’s disease population in the world in 2030. In this review, we present an overview of epidemiology and health economics status of Parkinson’s disease across China and discuss the risk factors of Parkinson’s disease and related complications. From the view of clinical research, we also discuss the current status of clinical trials, diagnostic biomarkers, treatment of Parkinson’s disease, tertiary network and post-occupation education in Chinese Parkinson’s disease clinics.
Appendix
Available only for authorised users
Literature
1.
2.
Zeng Y. Towards deeper research and better policy for healthy aging --using the unique data of Chinese longitudinal healthy longevity survey. China Economic J. 2012;5(2–3):131–49.PubMedCrossRef
3.
4.
Dorsey ER, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–6.PubMedCrossRef
5.
6.
7.
8.
9.
Wang SJ, et al. A door-to-door survey of Parkinson's disease in a Chinese population in Kinmen. Arch Neurol. 1996;53(1):66–71.PubMedCrossRef
10.
Wang SJ, et al. Parkinson's disease in kin-Hu, Kinmen: a community survey by neurologists. Neuroepidemiology. 1994;13(1–2):69–74.PubMedCrossRef
11.
Zhang ZX, et al. Prevalence of Parkinson’s disease and related disorders in the elderly population of greater Beijing, China. Mov Disord. 2003;18(7):764–72.PubMedCrossRef
12.
Chen RC, et al. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology. 2001;57(9):1679–86.PubMedCrossRef
13.
Li SC, et al. A prevalence survey of Parkinson’s disease and other movement disorders in the People’s Republic of China. Arch Neurol. 1985;42(7):655–7.PubMedCrossRef
14.
Woo J, et al. Prevalence of Parkinson's disease in a Chinese population. Acta Neurol Scand. 2004;109(3):228–31.PubMedCrossRef
15.
Zhang L, et al. The prevalence of PD in a nutritionally deficient rural population in China. Acta Neurol Scand. 2005;112(1):29–35.PubMedCrossRef
16.
Zhang ZX, et al. Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet. 2005;365(9459):595–7.PubMedCrossRef
17.
Chen CC, et al. Different prevalence rates of Parkinson's disease in urban and rural areas: a population-based study in Taiwan. Neuroepidemiology. 2009;33(4):350–7.PubMedCrossRef
18.
Liu Y, et al. Investigation on prevalence rate of Parkinson’s disease in population aged 55 years old and above in Kashi, Xinjiang between 2008 and 2009. Chin J Neurol. 2010;43(12):863–5.
19.
Yingxu M, et al. Analysis of related factors Parkinson's disease in Beihai of Guangxi area. J Brain Nerv Dis. 2018;8:503–6.
20.
Mengqing S, et al. Analysis of the prevalence and risk factors for Parkinson's disease in middle-aged and elderly residents of aerospace center hospital adjacent communities. Neural Inj Funct Reconstr. 2017;1:28–31.
21.
Yuxia C. Research on Parkinson's disease morbidity and Coorelation between treatment time and rehabilitation of elderly patients in Jiaxing. J Jiaxing Univ. 2007;3:90–2.
22.
Jianlong Z, et al. Analysis of prevalence and related factors in different national Parkinson's disease in Yili of Xinjiang area. J Xinjiang Med Univ. 2013;3:273–7.
23.
Guochuan Z, et al. A survey of prevalence of senile dementia and Parkinson's disease. J Clin Psychol Med. 2001;3:143–5.
24.
Hongqing Y, et al. Study on the prevalence of Parkinson's disease and its relationship with metabolic syndrome among the elderly in Luoxing street Mawei District. Chin J Pract Nerv Dis. 2017;24:79–82.
25.
Xiaorong G, et al. A cross-sectional study of Parkinson’s disease in northern Shanxi. Chin J Pract Nerv Dis. 2016;3:82–3.
26.
Bin Z, et al. Prevalence of Parkinson's disease in Shanghai urban and rural area. J Brain Nerv Dis. 2001;6:330–2.
27.
Luning W, et al. Study on the prevalence and relative factors of the Parkinson's disease in residents aged 35 years or older in Urumqi city. J Xinjiang Med Univ. 2013;3:278–281,286.
28.
Yang XL, et al. Related factors and prevalence of Parkinson’s disease among Uygur residents in Hetian, Xinjiang Uygur autonomous region. Genet Mol Res. 2015;14(3):8539–46.PubMedCrossRef
29.
Wang LN, et al. A cross-sectional study of neurological disease in the veterans of military communities in Beijing. Zhonghua Nei Ke Za Zhi. 2010;49(6):463–8.PubMed
30.
Zou YM, et al. The prevalence of Parkinson’s disease continues to rise after 80 years of age: a cross-sectional study of Chinese veterans. Eur Rev Med Pharmacol Sci. 2014;18(24):3908–15.PubMed
31.
Baocheng Y, et al. Prevalence of Parkinson's disease in elderly veterans. China Healthc Innov. 2007;19:102–3.
32.
Wang G, et al. Mortality from Parkinson’s disease in China: findings from a five-year follow up study in Shanghai. Can J Neurol Sci. 2015;42(4):242–7.PubMedCrossRef
33.
Zhang Y, et al. Mortality from Parkinson’s disease in China: findings from a ten-year follow up study in Shanghai. Parkinsonism Relat Disord. 2018;55:75–80.PubMedCrossRef
34.
Auyeung M, et al. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients. J Neurol Neurosurg Psychiatry. 2012;83(6):607–11.PubMedCrossRef
35.
36.
Chen W, et al. Prevalence of wearing-off and dyskinesia among the patients with Parkinson’s disease on levodopa therapy: a multi-center registry survey in mainland China. Transl Neurodegener. 2014;3(1):26.PubMedPubMedCentralCrossRef
37.
Zhang TM, et al. Nonmotor symptoms in patients with Parkinson disease: a cross-sectional observational study. Medicine (Baltimore). 2016;95(50):e5400.CrossRef
38.
39.
Li R, et al. Prevalence and risk factors of Parkinson’s disease comorbid anxiety and depression. Henan Med Res. 2019;28(1):31–3.
40.
Zhu J, et al. Prevalence and risk factors for visual hallucinations in Chinese patients with Parkinson's disease. J Neurol Sci. 2017;372:471–6.PubMedCrossRef
41.
Wang Q, et al. Assessment of cognitive impairment in patients with Parkinson's disease: prevalence and risk factors. Clin Interv Aging. 2014;9:275–81.PubMedPubMedCentral
42.
43.
Wen HB, et al. Epidemiology and clinical phenomenology for Parkinson's disease with pain and fatigue. Parkinsonism Relat Disord. 2012;18(Suppl 1):S222–5.PubMedPubMedCentralCrossRef
44.
Zhu XY, et al. Clinical characteristics of leg restlessness in Parkinson's disease compared with idiopathic restless legs syndrome. J Neurol Sci. 2015;357(1–2):109–14.PubMedCrossRef
45.
Wang G, et al. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov Disord. 2006;21(9):1439–43.PubMedCrossRef
46.
47.
Chan DK, et al. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J Neurol Neurosurg Psychiatry. 1998;65(5):781–4.PubMedPubMedCentralCrossRef
48.
Li X, et al. Association between cigarette smoking and Parkinson's disease: a meta-analysis. Arch Gerontol Geriatr. 2015;61(3):510–6.PubMedCrossRef
49.
Chen YK, et al. Anxiety disorders in Chinese patients with Parkinson's disease. Int J Psychiatry Med. 2010;40(1):97–107.PubMedCrossRef
50.
Zheng J, et al. Association between gene polymorphism and depression in Parkinson's disease: a case-control study. J Neurol Sci. 2017;375:231–4.PubMedCrossRef
51.
Kum WF, et al. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease. J Clin Neurosci. 2009;16(8):1034–7.PubMedCrossRef
52.
Chen S, et al. Circulating exosomal miRNAs as diagnostic biomarkers in Parkinson's disease. Eur Rev Med Pharmacol Sci. 2018;22(16):5278–83.
53.
Ding H, et al. Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease. Parkinsonism Relat Disord. 2016;22:68–73.PubMedCrossRef
54.
Chen Y, et al. MicroRNA-4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson's disease. Front Aging Neurosci. 2017;9:232.PubMedPubMedCentralCrossRef
55.
Cao XY, et al. MicroRNA biomarkers of Parkinson's disease in serum exosome-like microvesicles. Neurosci Lett. 2017;644:94–9.PubMedCrossRef
56.
Dong H, et al. A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson's disease. Biomarkers. 2016;21(2):129–37.PubMedCrossRef
57.
Ma W, et al. Serum miR-221 serves as a biomarker for Parkinson's disease. Cell Biochem Funct. 2016;34(7):511–5.PubMedCrossRef
58.
Wang X, et al. Detection of alpha-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease. Neurosci Lett. 2015;599:115–9.PubMedCrossRef
59.
60.
Mao W, et al. Pyrosequencing analysis of methylation levels of clock genes in leukocytes from Parkinson’s disease patients. Neurosci Lett. 2018;668:115–9.PubMedCrossRef
61.
62.
63.
Geng Y, et al. Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease. J Zhejiang Univ Sci B. 2005;6(1):22–7.PubMedCrossRef
64.
Jin R, et al. Validation of abnormal glucose metabolism associated with Parkinson's disease in Chinese participants based on 18F-fluorodeoxyglucose positron emission tomography imaging. Neuropsychiatr Dis Treat. 2018;14:1981–9.PubMedPubMedCentralCrossRef
65.
Zhang D, et al. Widespread increase of functional connectivity in Parkinson's disease with tremor: a resting-state FMRI study. Front Aging Neurosci. 2015;7:6.PubMedPubMedCentral
66.
Xu D, et al. Validation of Iodine-131-meta-iodobenzylguanidine cardiac scintigraphy in parkinsonism: a preliminary study. Parkinsonism Relat Disord. 2018;50:69–73.PubMedCrossRef
67.
Wang N, et al. Using ‘swallow-tail’ sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson's disease: a susceptibility-weighted imaging study. Eur Radiol. 2017;27(8):3174–80.PubMedCrossRef
68.
Li DH, et al. Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson's disease. Parkinsonism Relat Disord. 2015;21(8):923–8.PubMedCrossRef
69.
CMA. China guideline of treatment Parkinson's disease (3rd edition). Chin J Neurol. 2014;6:428–33.
70.
Chen S, et al. The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease. Transl Neurodegener. 2016;5:12.PubMedPubMedCentralCrossRef
71.
CMDS. Guideline of treatment of Parkinson’s disease. Chin J Neurol. 2006;39(6):409–12.
72.
Zhang ZX, et al. Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China. BMC Res Notes. 2014;7:65.PubMedPubMedCentralCrossRef
73.
Katzenschlager R, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008;71(7):474–80.PubMedCrossRef
74.
Hu X, et al. The different ablative procedures for Parkinson's disease and their effects. Shanghai Med J. 2002;25(2):69–72.
75.
Wu X, Cao X. Development and current situation of functional neurosurgery in treatment of Parkinson disease. Chin J Clin Med. 2017;24(6):839–44.
76.
Wenming Y, et al. Clinical routes of traditional Chinese medicine of Parkinson's disease. Clin J Tradit Chin Med. 2012;24(11):1122–4.
77.
Xiqun C, Dingfang C, zhen Z. Influence of Liver-Nourishing and wind-extinguishing formulas and drugs on rotating behavior in Parkinson rats. Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai. 2001;15(2):41–3.
78.
Ye Q, et al. Zishenpingchan granules for the treatment of Parkinson's disease: a randomized, double-blind, placebo-controlled clinical trial. Neural Regen Res. 2018;13(7):1269–75.PubMedPubMedCentralCrossRef
79.
Dingfang C, et al. Effect of Bushen Yanggan recipe on nigrostriatal function in parkinsonian model rats after long-term levodopa treatment. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002;22(1):43–6.
80.
Feng C, et al. Clinical research of the seven Acupoints of the Cranial Base (SACB) treatment to 114 Parkinson's disease patients. Chin J Basic Med Tradit Chin Med. 2013;5:547–548,573.
81.
Jingjing M, Wei W. Evaluation of massage and Yisanwuqi walking treatment to sleep disorders of Parkinson's disease. Chin J Pract Nurs. 2012;28(31):18–9.
82.
Zhihong G, et al. Influence of massage of abdominal acupoints to functional constipation of Parkinson's disease. Nurs J Chin PLA. 2013;30(5):72–73,76.
83.
Yang Y, et al. Tai chi for improvement of motor function, balance and gait in Parkinson's disease: a systematic review and meta-analysis. PLoS One. 2014;9(7):e102942.PubMedPubMedCentralCrossRef
84.
Su J, et al. Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson's disease models. Cell Death Dis. 2018;9(10):1020.PubMedPubMedCentralCrossRef
85.
Xiao CM, Zhuang YC. Effect of health Baduanjin qigong for mild to moderate Parkinson's disease. Geriatr Gerontol Int. 2016;16(8):911–9.PubMedCrossRef
86.
Xiao C, Zhuang Y, Kang Y. Effect of health qigong Baduanjin on fall prevention in individuals with Parkinson's disease. J Am Geriatr Soc. 2016;64(11):e227–8.PubMedCrossRef
87.
Song JH, et al. Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease. Eur Rev Med Pharmacol Sci. 2015;19(11):2001–7.PubMed
88.
Yingying Z, et al. Potential influencing factors of time from onset to clinical diagnosis and misdiagnosis rate of Parkinson's patients in Shanghai. Chin J Neurol. 2015;48(11):995–9.
89.
Breen DP, et al. Determinants of delayed diagnosis in Parkinson’s disease. J Neurol. 2013;260(8):1978–81.PubMedCrossRef
90.
Li J, et al. MDS clinical diagnostic criteria for Parkinson's disease in China. J Neurol. 2017;264(3):476–81.PubMedCrossRef
91.
Jing X. The effect of health education in patients with Parkinson's disease. China Health Stand Manag. 2015;16:27–8.
92.
93.
Ruiyun L. Effects of family synchronization health education on rehabilitation and quality of life in Parkinson disease patients. Chin J Mod Nurs. 2016;22(18):2625–9.
94.
Cuiping W. Observation on personalized education to Parkinson's disease. Int J Nurs. 2011;30(1):108–10.
95.
96.
Hu Y, Zhang Z. Skilled doctors in tertiary hospitals are already overworked in China. Lancet Glob Health. 2015;3(12):e737.PubMedCrossRef
97.
Mochang Q, Yihu F, Changhe C. Role of community physicians in early diagnosis of Parkinson's disease. Chin Gen Pract. 2014;27:3171–3173,3174.
98.
99.
Gao C, et al. Objective assessment of bradykinesia in Parkinson's disease using evolutionary algorithms: clinical validation. Transl Neurodegener. 2018;7:18.PubMedPubMedCentralCrossRef
100.
CMA. China Diagnostic criteria of Parkinson's disease (2016 Version). Chin J Neurol. 2016;49(4):268–71.
101.
CMA. Guideline of diagnosis and treatment of Parkinson's disease dementia. Chin J Neurol. 2011;44(9):635–7.
102.
CMA. Chinese experts consensus of diagnosis and treatment of vascular parkinsonism. Chin J Neurol. 2017;50(5):326–31.
103.
CMA. Guideline of diagnosis and treatment of dementia, anxiety and psychosis of Parkinson's disease. Chin J Neurol. 2013;46(1):56–60.
104.
CMA. Chinese expert consensus on clinical database construction of PD and movement disorders. Chin J Neurol. 2016;15(7):649–53.
105.
Chinese Expert Group on Deep Brain Stimulation of Parkinson's Disease. Chinese expert consensus on deep brain stimulation of Parkinson's disease. Chin J Neurol. 2012;45(7):541–3.
106.
Chinese Expert Group on Deep Brain Stimulation of Parkinson's Disease. Chinese expert consensus on programming of deep brain stimulation of Parkinson's disease. Chin J Neurosurg. 2016;32(12):1192–8.
107.
CMA. Chinese expert consensus document on the therapeutic uses of botulinum toxin. Chin J Neurol. 2018;51(10):779–86.
108.
109.
Metadata
Title
Parkinson’s disease in China: a forty-year growing track of bedside work
Authors
Gen Li
Jianfang Ma
Shishuang Cui
Yixi He
Qin Xiao
Jun Liu
Shengdi Chen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2019
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-019-0162-z

Other articles of this Issue 1/2019

Translational Neurodegeneration 1/2019 Go to the issue

Review

Alzheimer’s in a dish – induced pluripotent stem cell-based disease modeling

Review

Current progress of mitochondrial transplantation that promotes neuronal regeneration

Research

Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease

Research

Longitudinal diffusion tensor magnetic resonance imaging analysis at the cohort level reveals disturbed cortical and callosal microstructure with spared corticospinal tract in the TDP-43G298S ALS mouse model

Research

Clinicopathologic characterization and abnormal autophagy of CSF1R-related leukoencephalopathy

Research

Oscillation-specific nodal alterations in early to middle stages Parkinson’s disease